Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) EBITDA Margin (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed EBITDA Margin for 6 consecutive years, with 5.61% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin rose 765069.0% year-over-year to 5.61%, compared with a TTM value of 618.28% through Sep 2025, up 1353438.0%, and an annual FY2024 reading of 10933.75%, up 418896.0% over the prior year.
  • EBITDA Margin was 5.61% for Q3 2025 at Ovid Therapeutics, up from 80.88% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 84.73% in Q1 2021 and bottomed at 115329.27% in Q3 2022.
  • Average EBITDA Margin over 5 years is 14028.96%, with a median of 4726.27% recorded in 2022.
  • Peak annual rise in EBITDA Margin hit 10429365bps in 2023, while the deepest fall reached -2075618bps in 2023.
  • Year by year, EBITDA Margin stood at 84.73% in 2021, then crashed by -106bps to 5.47% in 2022, then tumbled by -201612bps to 11035.63% in 2023, then dropped by -28bps to 14107.89% in 2024, then surged by 100bps to 5.61% in 2025.
  • Business Quant data shows EBITDA Margin for OVID at 5.61% in Q3 2025, 80.88% in Q2 2025, and 5.61% in Q1 2025.